ALSO NOTED: FDA interviews for Singulair psych effects; Wal-Mart offers 90-day scrips for $10;

> The FDA is collecting personal stories of suicide and other unusual side effects from Merck's allergy med Singulair as part of a nine-month review of the drug's safety; parents of one teen are lobbying for a "black box" warning of mood changes and suicidal thoughts. Report

> Wal-Mart said it's rolling out a new phase of its generic-drugs program, promising to fill many 90-day scrips for $10 and offering several women's meds--including the cancer drug Tamoxifen--for $9 a month or $24 for a 90-day supply. Report

> New Zealand's government drug-buying agency has started a court-ordered study on whether it should fund 12-month courses of the breast cancer drug Herceptin, rather than the nine-week course it now pays for. Report

> GlaxoSmithKline inked a deal to sell Japan-based Astellas Pharma's injectable anti-fungal Micafungin in India. Report

> A slowdown in pharma has braked sales of Applied Biosystems' mass spectrometers, depressing overall quarterly revenue growth to 4.3 percent. Report

> Boehringer Ingelheim got European approval for use of its Aptivus drug in HIV-positive patients resistant to commonly prescribed meds. Report

> Employees at a former Merck plant in Karachi, Pakistan, are balking at the loss of their stock options after the plant was sold to Organon BioSciences. Report

> Pfizer is still hunting for buyers for two factories in Cork, Ireland, some 15 months after putting those facilities on the market. Report

> Alpharma posted a tenfold rise in first-quarter profits, to $163.1 million, on a leap in revenues from its Flector pain patch. Report

> Novartis' painkiller Voveran has overtaken Pfizer's Corex cough syrup as the fastest-selling drug in India. Report

> In an effort to bring expenses in line with revenues, Valeant is cutting 130 workers in the U.S. and Mexico. Report

> Discovery Labs has been dealt another blow in its quest to gain approval for Surfaxin, a treatment for premature infant respiratory distress syndrome. Report

> Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals' drug candidate, MEM 3454, for various neurological and psychiatric disorders. Report

> Critical Therapeutics is merging with Cornerstone BioPharma Holdings, a specialty pharmaceutical company that develops treatments for respiratory disorders. Report

And Finally... Another windfall from the Neurontin marketing settlement: Consumers Union has nabbed a $4.4 million grant to distribute free, unbiased prescription drug info. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.